CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 67 enrolled
Drug / intervention
pharmacogenetic sampling +1 moregenetic
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01109147
NCT01109147Phase 4Completed
CompareCT.gov

Comparison of the Effects of Aripiprazole and Risperidone on the Pattern of Brain Activation in Schizophrenic Patients During Emotional Tasks and With Reference to Controls

Qualissima·interventional·Posted Apr 23, 2010·Updated Apr 9, 2014

In Brief

A Phase 4 clinical trial evaluating Imagery and pharmacogenetic sampling for Schizophrenia, Undifferentiated Type. Completed, enrolled 67 participants across 2 sites.

Detailed Summary

After an initial screening visit, including an assessment of psychiatric disorders, patients stabilized on antipsychotic medication (aripiprazole or risperidone) for at least 6 weeks and control subjects will undergo an assessment using functional magnetic resonance imaging (fMRI) of the differences of patterns of brain activation during an emotional task

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSchizophrenia, Undifferentiated Type
CountriesFrance
Collaborators--

Timeline

Phase 4CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedApr 23, 2010
Enrollment StartDec 1, 2010
Primary CompletionJan 1, 2013
Study CompletionMay 1, 2013
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 16.2 years ago

Interventions

Imageryother

All the subject will be submitted to an functional magnetic resonance imaging (fMRI) examination.

pharmacogenetic samplinggenetic

A pharmacogenetic sample will be done with an additional consentment.